Stocksigma LogoStocksigma Logo

Anuh Pharma Reports Strong H1 FY27 Profitability With Significant Margin Expansion

In H1 FY27, Anuh Pharma posted operating revenue of Rs 379.05 Cr, up 1.80% YoY, prioritizing higher-value products over volume

Anuh Pharma Reports Strong H1 FY27 Profitability With Significant Margin Expansion

Anuh Pharma Ltd · Investor Presentation · 06 Nov 2026, 8:28 pm

Anuh Pharma Reports Strong H1 FY27 Profitability With Significant Margin Expansion In H1 FY27, Anuh Pharma posted operating revenue of Rs 379.05 Cr, up 1.80% YoY, prioritizing higher-value products over volume. EBITDA surged 39.11% YoY to Rs 36.92 Cr as EBITDA margin expanded 261 bps to 9.74%. PAT jumped 42.25% YoY to Rs 22.64 Cr, while production grew 15.31% YoY to 987 MT. The company remains net debt-free with ROCE reaching 16.52%. Following the commissioning of its Tarapur Unit F-10, raising total capacity to 2,975 MTPA, management targets 15–20% annual growth driven by export recovery and pipeline commercialization.

Original exchange filing (PDF)

More announcements from Anuh Pharma Ltd

All Anuh Pharma Ltd announcements